Equities

Solara Active Pharma Sciences Ltd

SOLARA:NSI

Solara Active Pharma Sciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)749.50
  • Today's Change11.50 / 1.56%
  • Shares traded53.62k
  • 1 Year change+127.67%
  • Beta1.3015
Data delayed at least 15 minutes, as of Sep 20 2024 11:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform0
Hold0
Sell0
Strong Sell1

Share price forecast in INR

The 2 analysts offering 12 month price targets for Solara Active Pharma Sciences Ltd have a median target of 426.83, with a high estimate of 485.00 and a low estimate of 368.66. The median estimate represents a -42.49% decrease from the last price of 742.20.
High-34.7%485.00
Med-42.5%426.83
Low-50.3%368.66

Earnings history & estimates in INR

On Jan 25, 2023, earnings of 0.111 per share. This result exceeded the -0.92 consensus loss of the one analyst covering the company
Average growth rate+39.26%
Solara Active Pharma Sciences Ltd reported annual 2024 losses of -104.78 per share on May 29, 2024.
Average growth rate-545.18%
More ▼

Revenue history & estimates in INR

Solara Active Pharma Sciences Limited had 1st quarter 2025 revenues of 3.63bn. This was 3.17% above the prior year's 1st quarter results.
Average growth rate+5.24%
Solara Active Pharma Sciences Limited had revenues for the full year 2024 of 12.89bn. This was 10.73% below the prior year's results.
Average growth rate+0.40%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.